HealthEquity, Inc. (HQY) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 10Y.
- Score
- 30/100
- 10Y CAGR
- 26.3%
- Median YoY
- 18.8%
- YoY volatility
- σ 27.1pp· choppy
- Quarters ≥ 20%
- 19 of 40
- Negative quarters
- 2
- Valuation vs own 10Y history
- Latest historical P/S 5.6x · 10Y median 7.3x · 9th percentile · as of Oct 6, 2026
How this score is computed
- Quarters at or above 20%: 19 of 40 → 19 of 40 pts
- Steadiness (typical swing 27.1pp) → 5.6 of 25 pts
- Pace (median 18.8% YoY) → 5.1 of 20 pts
- Latest quarter (7.6% YoY) → 0 of 15 pts
- Score: 30 of 100
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Across metrics · 10Y
| Metric | 10Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 26.3% | 18.8% | 27.1pp | 19 of 40 | 2 |
| EPSEPS | 24.3% | 40% | 76.2pp | 18 of 40 | 9 |
| Op cash flowOperating cash flow | 32.9% | 37.5% | 47.8pp | 25 of 40 | 9 |
| EBITDAEBITDA | 29.9% | 29% | 31.4pp | 26 of 40 | 8 |
| FCFFree cash flow | — | 14.1% | 66.8pp | 15 of 40 | 14 |
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: HQY on the compounders surface · All compounders, ranked